Neurofilaments are the neuron's own intermediate filaments — type-IV proteins (light, medium, heavy chains plus α-internexin and nestin) whose heteropolymers fill the axon's cross-section and set its calibre: more neurofilament, wider axon, faster conduction. They are also neurology's newest biomarker: the light chain (NfL) measurable in a drop of blood rises with any process that damages axons — ALS, MS flares, Alzheimer's, head trauma — making "neurofilament" a word that moved from cell biology into daily neurology clinics.
Each other (co-assemble), motor proteins for slow axonal transport
Structure
All three chains share the rod domain; the M and H chains carry long KSP-repeat tails that phosphorylate and project side-arms — the brushes that hold neighbouring filaments at spacing and set axon radius.
Tail phosphorylation (by Cdk5, JNK, MAPK — see MAPK) is developmentally and regionally regulated; tau does the analogous job on microtubules, see tau.
The 10-nm rope's nonpolar architecture fits the axon's need: a stable lattice slowly transported from the cell body.
Function
Calibre and speed: large myelinated axons (the fastest conductors) are neurofilament-rich; radial growth is the cytoskeletal decision that sets conduction velocity.
Axon integrity: the lattice maintains morphology over the metre-long spans of motor and sensory axons — structural continuity at scales no other cell manages.
Slow transport: neurofilaments themselves ride the axonal tracks at ~1 mm/day with kinesin and dynein, pausing long between runs.
Regulation
Subunit expression follows neuron type and maturation; phosphorylation of the tails adjusts interfilament spacing.
Calcium-activated proteases (calpains) cut filaments in injury; the released NfL is the blood biomarker's source.
Turnover balances synthesis in the soma with degradation at the terminal — the axon's steady state.
Interactions
With microtubules and their motors: neurofilament transport and the axonal lattice's interweaving.
With neuronal metabolism: ALS-linked aggregations of neurofilaments were among the disease's first-described hallmarks.
With myelin's signals: radial growth is tuned by axon-oligodendrocyte contact — the growth-regulated coupling of caliber to conduction.
Clinical Relevance
Biomarker: serum/plasma NfL (Simoa assays) tracks axonal injury across ALS (prognosis), MS (treatment response), Alzheimer's, Parkinson's, and traumatic brain injury — neurology's C-reactive-protein moment.
Genetic disease: NEFL mutations cause Charcot-Marie-Tooth neuropathies (types 2E, 1F); NEFH variants modify ALS risk.
Histopathology: neurofilament staining dates axons in nerve biopsies and marks neurons' tumors (neuroblastoma's differentiation).